Brain Injury Association Logo

WE'D LIKE TO THANK OUR SPONSORS:
 

BIAA HOME : WORKING IN BRAIN INJURY : RESEARCH

Brain Injury Research

The Brain Injury Association of America (BIAA) does not currently fund research but advocates for increased funding from public and private sectors, promotes participation in research studies and disseminates research findings to individuals with brain injury, their family members and the professionals who provide treatment and long-term care.

BIAA collaborates with the nation's leading brain injury research centers, such as the TBI Model Systems, to abstract the findings published in professional journals into brief, easy-to-read articles. By translating scientific discoveries into useful and practical knowledge for consumers and the general public, BIAA and its partners help improve the quality and relevance of brain injury research and treatment. A database of the Model Systems abstracts can be accessed here.

Current Research Studies Needing Participants 

 Topic PRISM II is a real-world registry to study the safety and effectiveness of NUEDEXTA in the treatment of pseudobulbar affect (PBA) in stroke, dementia and traumatic brain injury (TBI) patients.
 Description

Pseudobulbar affect is a neurologic condition that can occur in people with certain brain diseases or brain injuries that damage the areas of the brain that control normal expression of emotion. PBA results in uncontrollable, involuntary episodes of crying or laughing that are often sudden and exaggerated or do not match what the person is feeling inside. PBA episodes are disruptive and can limit everyday interactions with other people.

Nearly 2 million Americans with certain neurologic conditions or brain injuries are estimated to suffer from PBA. PBA can affect men and women, old and young.

PRISM II is a 12-week long study testing the safety and effectiveness of NUEDEXTA in the treatment of PBA in patients who had a stroke, had a brain injury, or have dementia.

NUEDEXTA is FDA-approved for the treatment for PBA. NUEDEXTA is a combination of two drugs, dextromethorphan and quinidine and is thought to act on areas on the brain responsible for emotional responses.

During the three-month duration of the study, participants will be asked to visit the investigator site three times for safety and effectiveness measures and study-related examinations.

There are no costs to participate.
Participants will receive study-related medical care at no cost.
Participants will receive study medication at no cost.

NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) 20mg/10mg capsules can interact with other medications and can cause side effects, some of which may be serious. NUEDEXTA is contraindicated in patients taking certain drugs and in patients with specific cardiovascular risk factors. These are not all the risks from use of NUEDEXTA. Please see the important safety information and full prescribing information.

 Contact

Participation in the study is only possible if you visit one of the qualified investigation sites. Your eligibility to participate in the study will be assessed upon your contacting or visiting the investigation site. This decision can only be made by the physicians who have been trained for the study.

To learn more about this study or to find out if a qualified study site is reachable for you (or your patients), please go to http://www.avanirclinicaltrials.com/prism-II or call 1 (855) 477-4762.
Close Date
Open


BIAA Research Council

The BIAA Research Council, a committee of the Board of Directors, includes the following experts in the field of brain injury research:

Wayne A. Gordon, PhD, ABPP/Cn, Council Chairman
Jack Nash Professor, Department of Rehabilitation Medicine
Mount Sinai School of Medicine

Keith D. Cicerone, PhD, ABPP-Cn
Neuropsychology & Cognitive Rehabilitation
JFK-Johnson Rehabilitation Institute

Steven R. Flanagan, MD
Professor, NYU Langone Medical Center
Chair, Department of Rehabilitation Medicine
Member, NYU Physical Medicine and Rehabilitation

David A. Hovda, PhD
Director, UCLA Brain Injury Research Center
Professor, Departments of Neurosurgery and of Molecular and Medical Pharmacology
David Geffen School of Medicine at UCLA

 
© 2014 Brain Injury Association of America. All Rights Reserved. Website Maintained by: Chicago Digital

BRAIN INJURY ASSOCIATION OF AMERICA
1608 Spring Hill Road, Suite 110 • Vienna, VA 22182 • Phone: 703-761-0750 • Fax: 703-761-0755
National Brain Injury Information Center (Brain Injury Information Only) 1-800-444-6443

Fact Sheets  •  Legal Notices  •  Advertise  •  CONTACT US